US FDA’s Cimerli Review By The Numbers

 
• By Sue Sutter
  
Drug Review Profile: Cimerli Chronology
Cimerli was the second biosimilar version of Lucentis approved in the US but the first deemed interchangeable. • Source: Shutterstock/Alamy

More from Biosimilars

More from Biosimilars & Generics